The US Food and Drug Administration has approved a new device for treating patients with chronic heart failure who are not suited for other interventions such as cardiac resynchronisation therapy. The device is indicated to improve a patient’s ability to perform a six-minute walk and improve his or her quality of life. These are patients who have a marked limitation of physical activity and who remain symptomatic despite receiving optimal medical therapy.
